The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Open accessAbstract
Most normal mammalian cells have a finite lifespan, thought to constitute a protective mechanism against unlimited proliferation. This phenomenon, called senescence, is driven by telomere attrition, which triggers the induction of tumour suppressors including p16(INK4a) (ref. 5). In cultured cells, senescence can be elicited prematurely by oncogenes; however, whether such oncogene-induced senescence represents a physiological process has long been debated. Human naevi (moles) are benign tumours of melanocytes that frequently harbour oncogenic mutations (predominantly V600E, where valine is substituted for glutamic acid) in BRAF, a protein kinase and downstream effector of Ras. Nonetheless, naevi typically remain in a growth-arrested state for decades and only rarely progress into malignancy (melanoma). This raises the question of whether naevi undergo BRAF(V600E)-induced senescence. Here we show that sustained BRAF(V600E) expression in human melanocytes induces cell cycle arrest, which is accompanied by the induction of both p16(INK4a) and senescence-associated acidic beta-galactosidase (SA-beta-Gal) activity, a commonly used senescence marker. Validating these results in vivo, congenital naevi are invariably positive for SA-beta-Gal, demonstrating the presence of this classical senescence-associated marker in a largely growth-arrested, neoplastic human lesion. In growth-arrested melanocytes, both in vitro and in situ, we observed a marked mosaic induction of p16(INK4a), suggesting that factors other than p16(INK4a) contribute to protection against BRAF(V600E)-driven proliferation. Naevi do not appear to suffer from telomere attrition, arguing in favour of an active oncogene-driven senescence process, rather than a loss of replicative potential. Thus, both in vitro and in vivo, BRAF(V600E)-expressing melanocytes display classical hallmarks of senescence, suggesting that oncogene-induced senescence represents a genuine protective physiological process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
From Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor (2008) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [225]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mouse models of melanoma and human nevi (both oncogene driven) show accumulation of SA-β-gal+–CDKN2A+ foci224,225.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [225]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This type of oncogene-induced senescence (OIS) is frequently observed in premalignant and benign tumour tissues [37 -39] but not in advanced malignant tumours, where cancer cells have already bypassed senescence.”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hallmarks of senescent cells were subsequently identified in dermal premalignant lesions, specifically human melanocytic naevi 81,82 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Studies in various mouse models, supported by correlative evidence from human- derived tissue samples, have underscored the tumour- suppressive role of OIS 81,120-123 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [81]
In the citing paper
“Oncogene-induced senescence protects against tumor initiation 34–37.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [35]
In the citing paper
“OIS is a powerful tumor suppressor mechanism 34–37.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [35]
In the citing paper
“in vitro experiments showed that cells that lack functional p53 or overexpress the H3K9me3 demethylase JMJD2c46,50 — which therefore cannot enter senescence in response to pro-senescent oncogenes such as Ras-G12V or Braf-V600E46,51 — also failed to enter VIS and lacked a SASP upon infection with SARS-CoV-2 (ref.28).”
From COVID-19 and cellular senescence (2023) · cites this paper as [51]
In the citing paper
“Studies have demonstrated high levels of senescence in premalignant lesions and lower levels in invasive disease, suggesting a role for senescence in blocking malignant progression [2,31,32].”
From Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies (2020) · cites this paper as [32]
In the citing paper
“human melanocytic naevi (an OIS model), remain non-proliferative for decades without transformation into malignant melanoma 25”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [25]
In the citing paper
“This is a seminal study that identified OIS of human melanocytic naevi.”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [25]
In the citing paper
“Senescence markers are detected in premalignant tumor lesions but not at later stages of tumor development [17,18,19].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Benign melanocytic lesions, which are melanoma precursors in humans, express high p16 and are an in vivo example of OIS [19,55].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Indeed, such telomeres are not visibly shorter than functional telomeres [114] in human melanocytic nevi with frequent BRAF mutations, a typical OIS feature in vivo [19].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Indeed, its locus is more commonly deleted or silenced than mutated in melanoma, the more malignant later stage of disease [19,55].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“For example, N-RAS- or B-RAF-activating mutations are commonly found in benign melanocytic nevi that show features of senescence, such as elevated p16 levels, but that do not express appreciable levels of ARF or p53 [19,55].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“In humans, Ras activation appears to induce only p16 [19,127].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“senescence occurs during the formation of benign cutaneous melanocytic nevi that express an oncogenic form of BRAF [19].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Importantly, this work also provided evidence for the occurrence of 4N senescent cells in human melanocyte naevi, the first in vivo senescence model, 94 suggesting that the G2 exit program has a more general role in senescence.”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [94]
In the citing paper
“The acronym oncogene-induced senescence (OIS) was coined following the demonstration that the aberrant activation of oncogenes (e.g., Ras, BRAF V600E, and c-Myc) or loss of tumor suppressor genes (e.g., PTEN) temporarily arrests a large variety of tumors in a pre-malignant state 180-183 (Figure 3B).”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [182]
In the citing paper
“BRAFV600E mutation alone is often insufficient to drive malignant transformation of melanocytes24.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [24]
In the citing paper
“For example, developmental senescent cells express p21WAF1/Cip1 but not p16INK4a9,10, while the reverse is observed in melanocytic nevi36,37.”
From Algorithmic assessment of cellular senescence in experimental and clinical specimens (2021) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Reversal of human cellular senescence: roles of the p53 and p16 pathways
Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg417 · Cited by 1,457
Lowe, S. W., Cepero, E., & Evan, G. I. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,374
Research works printed but not linked: 1
- Peeper, D. S. & Mooi, W. J. Pathogenesis of melanocytic naevi: growth arrest linked with cellular senescence? Histopathology 41, S139–S143 (2002)
Cited by
Sorted by citations
Items 601–700 of 1,009
Yates, K. E., Korbel, G. A., Shtutman, M., Roninson, I. B., & DiMaio, D. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00411.x · Cited by 77
The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence
Haferkamp, S., Tran, S. L., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2009) · Aging · doi:10.18632/aging.100051 · Cited by 77
Serrated pathway: Alternative route to colorectal cancer
Patai, Á. V. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i5.607 · Cited by 77
Mimeault, M., & Batra, S. K. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.12.001 · Cited by 77
The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: Friend or foe?☆
Andersen, J. B., & HASSEL, B. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.10.001 · Cited by 77
The Role of p16INK4a Pathway in Human Epidermal Stem Cell Self-Renewal, Aging and Cancer
D’Arcangelo, D., Tinaburri, L., & Dellambra, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071591 · Cited by 77
Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression
Rielland, M., Cantor, D. J., Graveline, R., Hajdu, C., Mara, L., de Diego Diaz, B., Miller, G., & David, G. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72619 · Cited by 76
The long non-coding RNA MIR31HG regulates the senescence associated secretory phenotype
Montes, M., Lubas, M., Arendrup, F. S., Mentz, B., Rohatgi, N., Tumas, S., Harder, L. M., Skanderup, A. J., Andersen, J., & Lund, A. H. (2021) · Nature Communications · doi:10.1038/s41467-021-22746-4 · Cited by 76
The controversial role of senescence-associated secretory phenotype (SASP) in cancer therapy
Cao, L., Li, K., Li, Q., Tong, Q., Wang, Y., & Huang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02475-8 · Cited by 79
Genetic alterations in melanocytic tumors
Takata, M., & Saida, T. (2006) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2006.05.002 · Cited by 76
In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells
Leikam, C., Hufnagel, A., Otto, C., Murphy, D. J., Mühling, B., Kneitz, S., Nanda, I., Schmid, M., Wagner, T. U., Haferkamp, S., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.71 · Cited by 76
Pathological and Molecular Advances in Pediatric Low-Grade Astrocytoma
Rodríguez, F. J., Lim, K. S., Bowers, D. C., & Eberhart, C. G. (2012) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164009 · Cited by 76
The role of mitogen‐ and stress‐activated protein kinase pathways in melanoma
Lopez‐Bergami, P. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00908.x · Cited by 75
Lamina Associated Domains and Gene Regulation in Development and Cancer
Lochs, S. J. A., Kefalopoulou, S., & Kind, J. (2019) · Cells · doi:10.3390/cells8030271 · Cited by 75
Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis
Wang, G., Chan, C., Gao, Y., & Lin, H. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10319 · Cited by 75
Pro- and anti-tumorigenic functions of the senescence-associated secretory phenotype
Lau, L., & David, G. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1565658 · Cited by 74
The Regulation of Cellular Functions by the p53 Protein: Cellular SenescencePreprint
Tonnessen-Murray, C. A., Lozano, G., & Jackson, J. G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026112 · Cited by 76
Molecular Pathways: Involving Microenvironment Damage Responses in Cancer Therapy Resistance
Sun, Y., & Nelson, P. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0768 · Cited by 74
Kim, Y. Y., Um, J., Yoon, J.-H., Lee, D., Lee, Y. J., Kim, D. H., Park, J., & Yun, J. (2019) · The FASEB Journal · doi:10.1096/fj.201901747rr · Cited by 74
Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma
Wang, A., & Qi, X. (2013) · IUBMB Life · doi:10.1002/iub.1193 · Cited by 74
Parallel pathways in RAF-induced senescence and conditions for its reversion
Jeanblanc, M., Ragu, S., Gey, C., Contrepois, K., Courbeyrette, R., Thuret, J., & Mann, C. (2011) · Oncogene · doi:10.1038/onc.2011.481 · Cited by 74
The emerging role of p53 in stem cells
Bonizzi, G., Cicalese, A., Insinga, A., & Pelicci, P. G. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.08.002 · Cited by 74
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
Durban, V. M., Deuker, M. M., Bosenberg, M., Phillips, W. A., & McMahon, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69619 · Cited by 74
Somatic p16INK4a loss accelerates melanomagenesis
Monahan, K. B., Rozenberg, G. I., Krishnamurthy, J., Johnson, S. M., Liu, W., Bradford, M. K., Horner, J. W., DePinho, R. A., & Sharpless, N. E. (2010) · Oncogene · doi:10.1038/onc.2010.314 · Cited by 74
p53 Mediates Senescence-Like Arrest Induced by Chronic Replicational Stress
Marusyk, A., Wheeler, L. J., Mathews, C. K., & DeGregori, J. V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01316-06 · Cited by 74
Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype
Jeon, H.-Y., Kim, J.-K., Ham, S. W., Oh, S.-Y., Kim, J., Park, J.-B., Lee, J.-Y., Kim, S.-C., & Kim, H. (2016) · Tumor Biology · doi:10.1007/s13277-015-4439-2 · Cited by 73
SETD1A protects from senescence through regulation of the mitotic gene expression program
Tajima, K., Matsuda, S., Yae, T., Drapkin, B. J., Morris, R. T., Boukhali, M., Niederhoffer, K., Comaills, V., Dubash, T. D., Nieman, L. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10786-w · Cited by 73
Misawa, T., Tanaka, Y., Okada, R., & Takahashi, A. (2020) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13928 · Cited by 73
NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma
Flockhart, R. J., Armstrong, J. L., Reynolds, N. J., & Lovat, P. E. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605277 · Cited by 73
Genetic and environmental melanoma models in fish
Patton, E. E., Mitchell, D. L., & Nairn, R. S. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00693.x · Cited by 73
Molecular Network Associated with MITF in Skin Melanoma Development and Progression
Yajima, I., Kumasaka, M. Y., Thang, N. D., Goto, Y., Takeda, K., Iida, M., Ohgami, N., Tamura, H., Yamanoshita, O., Kawamoto, Y., et al. (2011) · Journal of Skin Cancer · doi:10.1155/2011/730170 · Cited by 73
c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
Smalley, K. S. M., Sondak, V. K., & Weber, J. S. (2009) · PubMed · doi:10.14670/hh-24.643 · Cited by 73
Loss of lamin B receptor is necessary to induce cellular senescence
Lukášová, E., Kovařı́k, A., Bačı́ková, A., Falk, M., & Kozubek, S. (2016) · Biochemical Journal · doi:10.1042/bcj20160459 · Cited by 73
The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function
Wan, L., Chen, M., Cao, J., Dai, X., Yin, Q., Zhang, J., Song, S.-J., Lu, Y., Liu, J., Inuzuka, H., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0647 · Cited by 73
Erdheim-Chester Disease: a Concise Review
Papo, M., Emile, J., Maciel, T. T., Bay, P., Baber, A., Hermine, O., Amoura, Z., & Haroche, J. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0865-2 · Cited by 73
The thorny path linking cellular senescence to organismal aging
Patil, C. K., Mian, S. I., & Campisi, J. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.08.001 · Cited by 73
Premature aging/senescence in cancer cells facing therapy: good or bad?
Calvo, L., Ghadaouia, S., Martinez, A., & Rodier, F. (2015) · Biogerontology · doi:10.1007/s10522-015-9593-9 · Cited by 74
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor
Becker, T. M., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G. M., Scolyer, R. A., Mann, G. J., Kefford, R. F., Zhang, X. D., et al. (2013) · Oncogene · doi:10.1038/onc.2013.45 · Cited by 72
A genome-wide scan for naevus count: linkage to CDKN2A and to other chromosome regions
Zhu, G., Montgomery, G. W., James, M. R., Trent, J. M., Hayward, N. K., Martin, N. G., & Duffy, D. L. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201729 · Cited by 72
Badal, B., Solovyov, A., Cecilia, S. D., Chan, J. M., Chang, L., Iqbal, R., Aydin, I. T., Rajan, G. S., Chen, C., Abbate, F., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92102 · Cited by 72
KLF9-dependent ROS regulate melanoma progression in stage-specific manner
Bagati, A., Moparthy, S., Fink, E. E., Bianchi, A., Yun, D. H., Kolesnikova, M., Udartseva, O. O., Wolff, D. W., Roll, M. V., Lipchick, B. C., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0689-6 · Cited by 72
Self-citationLiu, W., Qi, M., Konermann, A., Zhang, L., Jin, F., & Jin, Y. J. (2015) · Aging · doi:10.18632/aging.100728 · Cited by 72
Zalaudek, I., Hofmann‐Wellenhof, R., Kittler, H., Argenziano, G., Ferrara, G., Petrillo, L., Kerl, H., & Soyer, H. P. (2007) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2007.06384.x · Cited by 71
Cdk2: a key regulator of the senescence control function of Myc
Hydbring, P., & Larsson, L. (2010) · Aging · doi:10.18632/aging.100140 · Cited by 71
S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis
Martínez-Leal, J. F., Ferrer, I., Blanco‐Aparicio, C., Hernández‐Losa, J., y Cajal, S. R., Carnero, A., & LLeonart, M. E. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn198 · Cited by 71
Wu, P., Hong, S., Veeranki, S., Karkhanis, M. S., Starenki, D., Plaza, J. A., & Park, J. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00021-13 · Cited by 71
Molecular Pathology of Skin Neoplasms of the Head and Neck
Kraft, S., & Granter, S. R. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0157-ra · Cited by 71
A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence
Acevedo, M., Vernier, M., Mignacca, L., Lessard, F., Huot, G., Moiseeva, O. V., Bourdeau, V., & Ferbeyre, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2347 · Cited by 70
Zhang, Y., Yang, B., Wang, J., Cheng, F., Shi, K., Ying, L., Wang, C., Xia, K., Huang, X., Gong, Z., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9503562 · Cited by 70
DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A
Leon, K. E., Buj, R., Lesko, E., Dahl, E. S., Chen, C.-W., Tangudu, N. K., Imamura-Kawasawa, Y., Kossenkov, A. V., Hobbs, R. P., & Aird, K. M. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202008101 · Cited by 70
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation
Mishra, P. J., Ha, L., Rieker, J., Sviderskaya, E. V., Bennett, D. C., Oberst, M. D., Kelly, K., & Merlino, G. T. (2010) · Oncogene · doi:10.1038/onc.2009.521 · Cited by 70
Sclafani, F., Gullo, G., Sheahan, K. D., & Crown, J. P. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.003 · Cited by 70
Wnt signaling potentiates nevogenesis
Pawlikowski, J. S., McBryan, T., van Tuyn, J., Drotar, M. E., Hewitt, R. N., Maier, A. B., King, A., Blyth, K., Wu, H. G., & Adams, P. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303491110 · Cited by 70
Kitago, M., Koyanagi, K., Nakamura, T., Goto, Y., Faries, M. B., O'Day, S. J., Morton, D. L., Ferrone, S., & Hoon, D. S. �. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.116467 · Cited by 70
The HBP1 Transcriptional Repressor Participates in RAS-Induced Premature Senescence
Zhang, X., Kim, J., Ruthazer, R., McDevitt, M. A., Wazer, D. E., Paulson, K. E., & Yee, A. S. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00604-06 · Cited by 70
TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation
Vallarelli, A. F. A., Rachakonda, P. S., André, J., Heidenreich, B., Riffaud, L., Bensussan, A., Kumar, R., & Dumaz, N. (2016) · Oncotarget · doi:10.18632/oncotarget.10634 · Cited by 70
Wang, Y., Chen, S., Yan, Z., & Pei, M. (2019) · Cell & Bioscience · doi:10.1186/s13578-018-0264-9 · Cited by 69
Giorgio, E. D., Paluvai, H., Dalla, E., Ranzino, L., Renzini, A., Moresi, V., Minisini, M., Picco, R., & Brancolini, C. (2021) · Genome biology · doi:10.1186/s13059-021-02340-z · Cited by 69
Falcinelli, M., Thaker, P. H., Lutgendorf, S. K., Conzen, S. D., Flaherty, R. L., & Flint, M. S. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0684 · Cited by 69
Davis, T., & Kipling, D. (2006) · Rejuvenation Research · doi:10.1089/rej.2006.9.402 · Cited by 69
Scope, A., Dusza, S. W., Marghoob, A. A., Satagopan, J. M., Braga, J. C. T., Psaty, E. L., Weinstock, M. A., Oliveria, S. A., Bishop, M., Geller, A. C., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.107 · Cited by 69
Polyclonality of BRAF Mutations in Acquired Melanocytic Nevi
Lin, J., Takata, M., Murata, H., Goto, Y., Kido, K., Ferrone, S., & Saida, T. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp309 · Cited by 69
Zhu, T., Zhang, H., Tao, J., Lu, S., Hu, X., Rong, R., & Xu, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s96535 · Cited by 69
Regulation of senescence escape by the cdk4–EZH2–AP2M1 pathway in response to chemotherapy
Duff, M. L., Gouju, J., Jonchère, B., Guillon, J., Toutain, B., Boissard, A., Henry, C., Guette, C., Lelièvre, E., & Coqueret, O. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0209-y · Cited by 69
Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune
van den Hurk, K., Niessen, H. E. C., Veeck, J., van den Oord, J. J., Steensel, M. A. M. V., Hausen, A. Z., van Engeland, M., & Winnepenninckx, V. J. L. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.011 · Cited by 68
Lee, S. Y., Ju, M. K., Jeon, H. M., Lee, Y. J., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1027453 · Cited by 69
In perspective: An update on telomere targeting in cancer
Sugarman, E. T., Zhang, G., & Shay, J. W. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23035 · Cited by 69
Self-citationKhalil, R., Diab‐Assaf, M., & Lemaître, J.-M. (2023) · Cells · doi:10.3390/cells12060915 · Cited by 68
Regulation of cellular senescence by the essential caveolar component PTRF/Cavin-1
Bai, L., Deng, X., Li, J., Wang, M., Li, Q., An, W., Deli, A., & Cong, Y. (2011) · Cell Research · doi:10.1038/cr.2011.56 · Cited by 68
High Frequency of p16 Promoter Methylation in NRAS-Mutated Cutaneous Melanoma
Jonsson, A., Tuominen, R., Grafström, E., Hansson, J., & Egyházi, S. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.216 · Cited by 68
Genetic alterations in main candidate genes during melanoma progression
Sini, M. C., Doneddu, V., Paliogiannis, P., Casula, M., Colombino, M., Manca, A., Botti, G., Ascierto, P. A., Lissia, A., Cossu, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23989 · Cited by 68
Li, Y., Shi, C., Yuan, J., Yang, Y., Li, J., Ma, J., Wu, X., Freund, M., Pollok, K. E., Hanenberg, H., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168138 · Cited by 68
The mechanisms and functions of IL-1β in intervertebral disc degeneration
Li, H., Wang, X., Pan, H., Xiao, C., Wang, C., Guo, S., Long, L., Shi, H., Chen, H., & Li, S. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112181 · Cited by 67
Kansal, R., Quintanilla‐Martínez, L., Datta, V., Lopategui, J. R., Garshfield, G., & Nathwani, B. N. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22010 · Cited by 67
The Cullin7 E3 ubiquitin ligase: A novel player in growth control
Sarikas, A., Xu, X., Field, L. J., & Pan, Z. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6922 · Cited by 67
Targeting BRAF in an Inducible Murine Model of Melanoma
Hooijkaas, A. I., Gadiot, J., van der Valk, M., Mooi, W. J., & Blank, C. U. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.002 · Cited by 67
Self-citationKim, E., Rebecca, V. W., Smalley, I., Messina, J. L., Mathew, R. A., Maria–Engler, S. S., Basanta, D., Smalley, K. S. M., & Anderson, A. R. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1720 · Cited by 67
Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Satoh, Y., Ishii, N., & Aoki, M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0927-t · Cited by 67
Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells
Antonangeli, F., Soriani, A., Ricci, B., Ponzetta, A., Benigni, G., Morrone, S., Bernardini, G., & Santoni, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1218105 · Cited by 67
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 68
Takata, M., Murata, H., & Saida, T. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00645.x · Cited by 66
Epigenetic Drivers of Genetic Alterations
Toyota, M., & Suzuki, H. (2010) · Advances in genetics · doi:10.1016/b978-0-12-380866-0.60011-3 · Cited by 66
RAS Transformation Requires CUX1-Dependent Repair of Oxidative DNA Damage
Ramdzan, Z. M., Vadnais, C., Pal, R., Vandal, G., Cadieux, C., Leduy, L., Davoudi, S., Hulea, L., Yao, L., Karnezis, A. N., et al. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001807 · Cited by 66
Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma
Anic, G. M., Sondak, V. K., Messina, J. L., Fenske, N. A., Zager, J. S., Cherpelis, B. S., Lee, J., Fulp, W. J., Epling‐Burnette, P. K., Park, J. Y., et al. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.02.010 · Cited by 66
Emerging roles of lnc RNA s in senescence
Montes, M., & Lund, A. H. (2016) · FEBS Journal · doi:10.1111/febs.13679 · Cited by 66
Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming
Buj, R., Chen, C., Dahl, E. S., Leon, K. E., Kuskovsky, R., Maglakelidze, N., Navaratnarajah, M., Zhang, G., Doan, M. T., Jiang, H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.084 · Cited by 66
p16INK4a‐induced senescence is disabled by melanoma‐associated mutations
Haferkamp, S., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00422.x · Cited by 66
Oncogenes and senescence: breaking down in the fast lanePreprint
Hemann, M. T., & Narita, M. (2007) · Genes & Development · doi:10.1101/gad.1514207 · Cited by 66
Kaufmann, W. K., Nevis, K. R., Qu, P., Ibrahim, J. G., Zhou, T., Zhou, Y., Simpson, D. A., Helms-Deaton, J., Cordeiro-Stone, M., Moore, D. T., et al. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700935 · Cited by 65
BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
Chen, B., Tardell, C., Higgins, B., Packman, K. E., Boylan, J. F., & Niu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042598 · Cited by 65
Senescence as a molecular target in skin aging and disease
Thau, H., Gerjol, B. P., Hahn, K., Gudenberg, R. W. V., Knoedler, L., Stallcup, K., Emmert, M. Y., Buhl, T., Wyles, S. P., Tchkonia, T., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102686 · Cited by 65
Analysis of the BRAFV600E Mutation in Central Nervous System Tumors
Myung, J. K., Cho, H., Park, C., Kim, S., Lee, S., & Park, S. (2012) · Translational Oncology · doi:10.1593/tlo.12328 · Cited by 65
Basile, K. J., Abel, E. V., & Aplin, A. E. (2011) · Oncogene · doi:10.1038/onc.2011.424 · Cited by 65
Gao, L. Y., Smit, M. A., van den Oord, J. J., Goeman, J. J., Verdegaal, E. M. E., van der Burg, S. H., Stas, M., Beck, S., Gruis, N. A., Tensen, C. P., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12096 · Cited by 65
Self-citationZeppernick, F. A., Ardighieri, L., Hannibal, C. G., VANG, R. S., Junge, J., Kjær, S. K., Zhang, R., Kurman, R. J., & Shih, I. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000313 · Cited by 65
Autophagy-mediated degradation of nuclear envelope proteins during oncogene-induced senescence
Lenain, C., Gusyatiner, O., Douma, S., van den Broek, B., & Peeper, D. S. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv124 · Cited by 65
Self-citationChoi, J., Xu, M., Makowski, M. M., Zhang, T., Law, M. H., Kovacs, M. A., Granzhan, A., Kim, W. J., Parikh, H. M., Gartside, M. G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3927 · Cited by 65
Cellular Senescence and Senotherapies in the Kidney: Current Evidence and Future Directions
Docherty, M. H., Baird, D., Hughes, J., & Ferenbach, D. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00755 · Cited by 66
Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression
Zhang, Z., Rosen, D. G., Yao, J. L., Huang, J., & Liu, J. (2006) · Modern Pathology · doi:10.1038/modpathol.3800655 · Cited by 65
Utility of Lesion Diameter in the Clinical Diagnosis of Cutaneous Melanoma
Abbasi, N. R., Yancovitz, M., Gutkowicz–Krusin, D., Panageas, K. S., Mihm, M. C., Googe, P. B., King, R., Prieto, V. G., Osman, I., Friedman, R. J., et al. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.4.469 · Cited by 65
Metadata
- Authors
- Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Michigan (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Mooi, Wolter J.
- Peeper, Daniel S.
- Venue
- Nature
- Published
- 2005-08
- Volume
- 436
- Issue
- 7051
- Pages
- 720-724
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2150740687
- Semantic Scholar
- bfbf433cb25b4a5e054e35a6850376801a03b87d
- Cited by
- 2,160
- References
- 31
- Citations by year
- 2026: 35 · 2025: 43 · 2024: 70 · 2023: 82 · 2022: 77 · 2021: 85 · 2020: 86 · 2019: 108 · 2018: 99 · 2017: 91 · 2016: 121 · 2015: 112 · 2014: 120 · 2013: 143 · 2012: 136
- FWCI
- 66.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- cellular senescence, BRAF V600E mutation, melanocytes, nevi, melanoma, cell cycle arrest, senescence-associated heterochromatin foci, SUV39H1, histone methyltransferase, p16INK4a, p53, PTEN, oncogene-induced senescence, tumor suppression
- MeSH terms
- beta-Galactosidase, Cell Cycle, Cell Line, Fibroblasts, Humans, Infant, Melanocytes, Nevus, Telomere, Cellular Senescence, In Situ Hybridization, Fluorescence, Cyclin-Dependent Kinase Inhibitor p16, Proto-Oncogene Proteins B-raf, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
